Gliomatosis Cerebri
Symptoms, Doctors, Treatments, Advances & More

Gliomatosis Cerebri Overview

Save information for later
Sign Up

Learn About Gliomatosis Cerebri

View Main Condition: Brain Tumor

What is the definition of Gliomatosis Cerebri?
Gliomatosis cerebri is a type of malignant (cancerous) brain tumor called a glioblastoma that develops from a specific type of brain cell called an astrocyte. It involves at least three sections (lobes) within the main part of the brain (cerebrum). It may also affect both sides of the cerebrum as well as the nerve cells within the brain (grey matter). There are two types of Gliomatosis cerebri. Type 1 (classic form) is characterized by scattered and widespread tumor cells and no apparent mass or tumor, while type 2 has similar characteristics in addition to a detectable mass or tumor. Signs and symptoms of Gliomatosis cerebri may include personality changes, memory disturbance, headaches, and seizures.
What are the alternative names for Gliomatosis Cerebri?
  • Gliomatosis cerebri
Who are the top Gliomatosis Cerebri Local Doctors?
Elite in Gliomatosis Cerebri
Dr. Roger Stupp
Hematology Oncology | Neurology | Hematology
Elite in Gliomatosis Cerebri
Dr. Roger Stupp
Hematology Oncology | Neurology | Hematology
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
312-695-4360
Experience:
39+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Roger Stupp is a Hematologist Oncology specialist and a Neurologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 39 years. Dr. Stupp is rated as an Elite provider by MediFind in the treatment of Gliomatosis Cerebri. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

Elite in Gliomatosis Cerebri
Dr. Jan Drappatz
Neurology
Elite in Gliomatosis Cerebri
Dr. Jan Drappatz
Neurology

UPMC Hillman Cancer Center

5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
412-530-4822
Languages Spoken:
English, French, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Jan Drappatz, MD, is a neuro-oncologist, an associate professor at the University of Pittsburgh School of Medicine, and the director of the Neuro-oncology program at UPMC. Dr. Drappatz specializes in the treatment of primary and metastatic brain tumors and neurologic complications of cancer. Dr. Drappatz is rated as an Elite provider by MediFind in the treatment of Gliomatosis Cerebri. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri. Dr. Drappatz is board certified in American Board Of Psychiatry And Neurology. Dr. Drappatz is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Gliomatosis Cerebri
Dr. Ian Pollack
General Surgery
Elite in Gliomatosis Cerebri
Dr. Ian Pollack
General Surgery

UPMC Children's Hospital Of Pittsburgh, Pediatric Neurological Surgery

4401 Penn Avenue, 
Pittsburgh, PA 
412-336-3075
Languages Spoken:
English
See accepted insurances

Ian Pollack, MD, is Chief of Pediatric Neurosurgery at UPMC Children’s Hospital of Pittsburgh, A. Leland Albright Professor of Neurosurgery, and vice-chair for Academic Affairs at the University of Pittsburgh School of Medicine. He is professor of clinical and translational science and distinguished professor of neurosurgery at the University of Pittsburgh. Dr. Pollack is rated as an Elite provider by MediFind in the treatment of Gliomatosis Cerebri. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Glioma, Gliomatosis Cerebri, Brain Tumor, Posterior Fossa Decompression, and Craniectomy. Dr. Pollack is board certified in American Board Of Neurological Surgery.

View All Doctors
What are the latest Gliomatosis Cerebri Clinical Trials?
A Trial to Evaluate Deoxyribonucleic) in BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B1)-Altered Glioma During Treatment With Plixorafenib Alone or With Retifanlimab
A Trial to Evaluate Deoxyribonucleic) in BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B1)-Altered Glioma During Treatment With Plixorafenib Alone or With Retifanlimab
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Phase: Early Phase 1

Summary: The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Combination product, Radiation
Study Phase: Phase 3

Summary: This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a random...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center